ADMA Biologics, Inc. (ADMA) Q2 2018 Earnings Results

ADMA Biologics Misses on EPS, Stock Down 1.75%

ADMA Biologics reported a loss per share of $0.35, but did not disclose revenue figures, leaving investors without a complete picture. The stock reacted negatively, declining by 1.75%, likely due to the lack of guidance and clarity on future performance. Investors may be concerned about the company's ability to navigate current market challenges without specific targets or revenue updates.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.35	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management acknowledged challenges in the current market environment. They emphasized ongoing efforts to enhance operational efficiency.

Management did not provide specific revenue figures or guidance for the upcoming quarters.

The focus remains on operational improvements and strategic initiatives.

ADMA Biologics Misses on EPS, Stock Down 1.75%

Key numbers

Management commentary

ADMA Biologics, Inc.

More earnings this week

ADMA Biologics Misses on EPS, Stock Down 1.75%

Key numbers

Management commentary